Hadassah Clinical Research Center
Jerusalem, Israel
NCT Number: NCT02073019
The purpose of this study is to determine whether BL-8040 is safe, tolerable and effective in the mobilization of Hematopoietic Stem Cells (HSC) in healthy volunteers
Looking for future studies?
Notify Me18 year–45 year
Male
Interventional
Phase 1
Jerusalem, Israel
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Up to 7 days after treatment comletion
BioLineRx, Ltd.
Industry
A Phase I, Two Part Study Exploring the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effect of Ascending Doses of BL-8040 in Healthy Subjects.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07362810
Hemato-oncologic Patients, Hematopoetic Stem Cell Transplantation
Zhengzhou, Henan, China
View Trial Details